ubiqi pitch deck
Embed Size (px)
Get insights. Better health.
Jacqueline Thongco-founder / CEO
Healthcare is not serving the patient...
OK, I’ll give it a try but I’ve already tried so many different meds!
I’m not sure what to recommend for your increased pain... maybe you can try this new drug?
Big data... big dealPower of secondary data lost if not used to change healthcare delivery
01 0 0
How can patient data be useful?
Personal Discovery Engine
PASSIVE MOBILE/DEVICE DATA
3RD PARTY DATA
Ubiqi provides a structured experiment framework
BASELINE SAMPLE HYPOTHESES
We power “citizen science” through n=1 experiments
A B B A
A A B B
RANDOMIZATION OUTCOME AGGREGATION
PATIENT:Identify triggersUnderstand symptomsCompare therapiesReport side-effects
HEALTHCARE ORGANIZATIONS:Understand patient behaviorAnalyze patient responseCompare therapiesReview safety data
Apply same framework across multiple conditions
pain respiratory gastrointestinal
We create value for many healthcare organizations
PHARMACY CHAINS PROVIDERS DISEASE
PHARMA HEALTHCARE IT (EMR)
$1-5PER USER PER MONTH
Software-as-a-Service revenue model
GROWS WITH USER BASEONE-TIME FEE
Addressable market is 63M people in US alone
250MAMERICANS COVERED BY HEALTH INSURANCE
125MHAVE CHRONIC CONDITION
63MBENEFIT FROM SELF-MANAGING
OUR ADDRESSABLE MARKET
Ubiqi has a unique approachACTIONABLE INSIGHTS
30+ years of experience in healthcare, technology, and design
Jacqueline Thong, CEOAnshuman Sharma, CTOWilliam Tang, Design Lead
ADVISORS ESTHER DYSONJAYANT PARTHASARATHY, PHDCHRIS ADAMS, MBA, PHDEGILIUS SPIERINGS, MD, PHDMATTHEW MAMET
We have strong resultsFrom initial migraine minimum viable product: 18K+ patients 20% active for more than 6 months Positive health outcomes!
REPLICATE MODEL FORBACK PAIN
MINIMUM VIABLE PRODUCT - Prove utility to patients- Gather data- Evaluate pharma interest- Validate pharma revenue model
REFINE PLATFORM - Prove clinical validity - Gather data- Scale pharma model- Evaluate payer interest
SCALE PLATFORM - Prove utility beyond migraine- Gather data- Validate payer revenue model
Payers are our key target; first build credibility
SCALE PHARMA MODEL
SCALE PAYER MODEL
2017 $75M REVENUE
Seeking guidance in partnership development and $700KKEY USE OF FUNDS FOR Q12013 - Q42013
R&DBusiness developmentCOGSAdminB2B MarketingUser acquisition
We envision acquisition by a payer or disease management company
Disease management companies
That’s great! Let’s work together to make that even better.
I saw that when I do yoga AND take the new meds, my daily pain scores are 20% lower!
Help us create this alternative future!
Get insights. Better health.
Jacqueline Thongco-founder / [email protected]+1 617 794 2089www.ubiqihealth.com
ROI to pharmaExample: Eli Lilly / Boehringer-Ingelheim’s Tradjenta
Revenues are $3.5B annually (2.3M pts)Adherence is 50% for oral anti-diabetic medicationsEstimated $1.75B revenue lost per year250K patients enroll in UbiqiAt $5 per patient per monthB-I PAYS UBIQI $1.25M (1 year)
10% of users get better results25K patients increase adherence to 75%B-I INCREASES REVENUES BY: +$47M (1 year)
ROI to payersExample: Aetna has 16 million subscribers
8% have asthma, costs them $2500/pt25% enroll in Ubiqi program: 320K subscribersAt $1 per member per month...AETNA PAYS UBIQI $3.8M (1 year)
25% of users get better results80K subscribers reduce ER visits, hospital visits, unnecessaryprescription meds, save $500 each/yrAETNA SAVES: $40M (1 year)
Intellectual PropertyItems we anticipate constitute defensible IP:i) process of taking structured / unstructured data and extractingfeature sets that are disease-specific and map to clinical evidence;
ii) learning engine which allows user to construct personalizedexperiments that they can run to create evidence;
iii) algorithm that makes suggestions on what pieces of anexperiment the user might want to choose to ensure success basedon base-line and crowd-sourced data;
iv) algorithm that aims to increase the information contained inunstructured patient-reported data to have stronger mappingbetween evidence and outcomes